Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 8/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | HINT1 | P49773 | 1/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22968509 | 1.00 | STING1 (0.52) | STING1PDE3BPDE3AHINT1NT5E | |
| Guanosine SCHEMBL1030863 | 0.89 | HPGD (0.63) | HINT1NT5EADORA3HPGDGSK3A | |
| SCHEMBL19049954 | 0.87 | HINT1 (0.51) | STING1PDE3BPDE3AHINT1NT5E | |
| SCHEMBL19049891 | 0.85 | STING1 (0.52) | STING1PDE3BPDE3AHINT1NT5E | |
| SCHEMBL20154870 | 0.83 | HINT1 (0.52) | STING1PDE3BPDE3AHINT1NT5E | |
| SCHEMBL19049941 | 0.82 | HINT1 (0.50) | STING1PDE3BPDE3AHINT1NT5E | |
| SCHEMBL7101375 | 0.81 | ADORA3 (0.53) | STING1PDE3BPDE3AHINT1NT5E | |
| SCHEMBL29908542 | 0.80 | ADORA3 (0.52) | STING1PDE3BPDE3AHINT1NT5E | |
| SCHEMBL1374868 | 0.79 | HINT1 (0.52) | STING1PDE3BPDE3AHINT1NT5E | |
| SCHEMBL3734057 | 0.79 | ADORA3 (0.51) | STING1PDE3BPDE3AHINT1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | Janssen Biopharma, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793859-B2 | Modified oligonucleotides and methods of use | NSUN2, ADAR, POLM | STING1 179/4885PDE3B 4110/4885PDE3A 4088/4885 |
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | STING1 179/4885PDE3B 4110/4885PDE3A 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.